Literature DB >> 14616788

No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections.

D C Kilpatrick1, L A McLintock, E K Allan, M Copland, T Fujita, N E Jordanides, C Koch, M Matsushita, H Shiraki, K Stewart, M Tsujimura, M L Turner, I M Franklin, T L Holyoake.   

Abstract

Chemotherapy causes neutropenia and an increased susceptibility to infection. Recent reports indicate that mannan-binding lectin (MBL) insufficiency is associated with an increased duration of febrile neutropenia and incidence of serious infections following chemotherapy for haematological malignancies. We aimed to confirm or refute this finding and to extend the investigation to the plasma ficolins, P35 (L-ficolin) and the Hakata antigen (H-ficolin). MBL, L-ficolin and H-ficolin were measured in 128 patients with haematological malignancies treated by chemotherapy alone or combined with bone marrow transplantation. Protein concentrations were related to clinical data retrieved from medical records. MBL concentrations were elevated compared with healthy controls in patients who received chemotherapy, while L-ficolin concentrations were decreased and H-ficolin levels were unchanged. There was no correlation between MBL, L-ficolin or H-ficolin concentration and febrile neutropenia expressed as the proportion of neutropenic periods in which patients experienced fever, and there was no relation between abnormally low (deficiency) levels of MBL, L-ficolin or H-ficolin and febrile neutropenia so expressed. Patients with MBL < or =0.1 microg/ml had significantly more major infections than no infections within the follow-up period (P<0.05), but overall most patients had signs or symptoms of minor infections irrespective of MBL concentration. Neither L-ficolin nor H-ficolin deficiencies were associated with infections individually, in combination or in combination with MBL deficiency. MBL, L-ficolin and H-ficolin, independently or in combination, did not have a major influence on susceptibility to infection in these patients rendered neutropenic by chemotherapy. These results cast doubt on the potential value of MBL replacement therapy in this clinical context.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616788      PMCID: PMC1808868          DOI: 10.1046/j.1365-2249.2003.02284.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Thermolabile beta-2 macroglycoprotein (Hakata antigen) in liver disease: biochemical and immunohistochemical study.

Authors:  T Fukutomi; B Ando; S Sakamoto; H Sakai; H Nawata
Journal:  Clin Chim Acta       Date:  1996-11-29       Impact factor: 3.786

2.  Detection of serum thermolabile beta-2 macroglycoprotein (Hakata antigen) by enzyme-linked immunosorbent assay using polysaccharide produced by Aerococcus viridans.

Authors:  M Tsujimura; C Ishida; Y Sagara; T Miyazaki; K Murakami; H Shiraki; K Okochi; Y Maeda
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.

Authors:  Charles G Mullighan; Sue Heatley; Kathleen Doherty; Ferenc Szabo; Andrew Grigg; Timothy P Hughes; Anthony P Schwarer; Jeff Szer; Brian D Tait; L Bik To; Peter G Bardy
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  P35, an opsonic lectin of the ficolin family, in human blood from neonates, normal adults, and recurrent miscarriage patients.

Authors:  D C Kilpatrick; T Fujita; M Matsushita
Journal:  Immunol Lett       Date:  1999-04-01       Impact factor: 3.685

5.  Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy.

Authors:  Olav J Bergmann; Michael Christiansen; Inga Laursen; Peter Bang; Niels Ebbe Hansen; Jørgen Ellegaard; Claus Koch; Vagn Andersen
Journal:  Eur J Haematol       Date:  2003-02       Impact factor: 2.997

6.  Association between deficiency of mannose-binding lectin and severe infections after chemotherapy.

Authors:  N A Peterslund; C Koch; J C Jensenius; S Thiel
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

7.  Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study.

Authors:  O Neth; I Hann; M W Turner; N J Klein
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

8.  Mannan binding lectin concentration and risk of miscarriage.

Authors:  D C Kilpatrick; L Starrs; S Moore; V Souter; W A Liston
Journal:  Hum Reprod       Date:  1999-09       Impact factor: 6.918

Review 9.  Mannan-binding lectin: clinical significance and applications.

Authors:  David C Kilpatrick
Journal:  Biochim Biophys Acta       Date:  2002-09-19

10.  Oligomeric structure and tissue distribution of ficolins from mouse, pig and human.

Authors:  T Ohashi; H P Erickson
Journal:  Arch Biochem Biophys       Date:  1998-12-15       Impact factor: 4.013

View more
  20 in total

1.  Association between mannan-binding lectin and impaired lung function in cystic fibrosis may be age-dependent.

Authors:  M S Muhlebach; S L MacDonald; B Button; J J Hubbard; M L Turner; R C Boucher; D C Kilpatrick
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis.

Authors:  M-L Metzger; I Michelfelder; S Goldacker; K Melkaoui; J Litzman; D Guzman; B Grimbacher; U Salzer
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

3.  Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.

Authors:  E Eleutherakis-Papaiakovou; M-A Dimopoulos; E Kastritis; D Christoulas; M Roussou; M Migkou; M Gavriatopoulou; D Fotiou; I Panagiotidis; D C Ziogas; N Kanellias; C Papadimitriou; E Terpos
Journal:  Bone Marrow Transplant       Date:  2017-08-14       Impact factor: 5.483

4.  Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.

Authors:  Jessica M van der Bol; Floris A de Jong; Ron H van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; Paul L van Daele; Jaap Verweij; Stefan Sleijfer; Ron H Mathijssen
Journal:  Oncologist       Date:  2010-10-07

Review 5.  Is there a role for mannan/mannose-binding lectin (MBL) in defence against infection following chemotherapy for cancer?

Authors:  N J Klein; D C Kilpatrick
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

6.  Ficolin-2 binds to HIV-1 gp120 and blocks viral infection.

Authors:  Fengling Luo; Tielong Chen; Jun Liu; Xihui Shen; Yinnan Zhao; Rongge Yang; Xiaolian Zhang
Journal:  Virol Sin       Date:  2016-08-29       Impact factor: 4.327

7.  H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients.

Authors:  L J Schlapbach; C Aebi; A G Hansen; A Hirt; J C Jensenius; R A Ammann
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

8.  L-ficolin in children with recurrent respiratory infections.

Authors:  A P M Atkinson; M Cedzynski; J Szemraj; A St Swierzko; L Bak-Romaniszyn; M Banasik; K Zeman; M Matsushita; M L Turner; D C Kilpatrick
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

9.  Mannose-binding lectin 2 polymorphisms do not influence frequency or type of infection in adults with chemotherapy induced neutropaenia.

Authors:  Michelle Wong; Lars Öhrmalm; Kristina Broliden; Carl Aust; Martin Hibberd; Thomas Tolfvenstam
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

Review 10.  The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics.

Authors:  Ingrid Evans-Osses; Iara de Messias-Reason; Marcel I Ramirez
Journal:  ScientificWorldJournal       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.